Related Experiment Video
Updated: Sep 30, 2025
Serum and Plasma Copy Number Detection Using Real-time PCR
Published on: December 15, 2017
AKR1B10 as a Potential Novel Serum Biomarker for Breast Cancer: A Pilot Study
Zhe Cao1,2, Kristin Delfino3, Vivek Tiwari4
1Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Background:
Aldo-keto reductase 1B10 (AKR1B10) is a secretory protein that is upregulated in breast cancer.
Objective:
This case-controlled pilot study evaluated the serum level of AKR1B10 in healthy women and patients with a localized or metastatic breast cancer.
Methods:
AKR1B10 levels were measured by ELISA and IHC in several patient cohorts.
Results:
Our data showed that serum AKR1B10 was significantly elevated in patients with localized (6.72 ± 0.92 ng/ml) or metastatic (7.79 ± 1.13 ng/ml) disease compared to cancer-free healthy women (1.69 ± 0.17 ng/ml) (p<0.001); the serum AKR1B10 was correlated with its expression in tumor tissues, but not with the tumor burden, molecular subtypes or histological stages. After surgical removal of primary tumors, the serum AKR1B10 was rapidly decreased within 3 days and plateaued at a level similar to that of healthy controls in most patients. ROC curve analysis suggested the optimal diagnostic cut-off value of serum AKR1B10 at 3.456 ng/ml with AUC 0.9045 ± 0.0337 (95% CI 0.8384 - 0.9706), sensitivity 84.75% (95% CI 73.01% to 92.78%), and specificity 93.88% (95% CI 83.13% to 98.72%).
Conclusions:
These data indicate the potential value of serum AKR1B10 as a biomarker of breast cancer.
More Related Videos
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
08:27Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
Published on: March 24, 2015